Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-arm Open-label Phase I/II Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

NCT06607692 is registered in ClinicalTrials.gov with Fundación de investigación HM as lead sponsor.

NCT NCT06607692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06607692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-arm Open-label Phase I/II Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Lead sponsor
Fundación de investigación HM
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 20, 2024
Completion date
December 31, 2029
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adrenal tumours, carcinoma adrenal, dipg, ependymoma, ependymoma recurrent, esthesioneuroblastoma, glioblastoma, glioblastoma (gbm), high grade gliomas, high risk neuroblastoma, medulloblastoma, medulloblastoma recurrent, meningioma, neuroblastoma recurrent, neuroendocrine tumours (net), osteosarcoma recurrent, paraganglioma, paraganglioma/ phaeochromocytoma, pheochromocytoma, solid tumor cancer, solid tumor refractory to conventional treatment, synovial sarcomas